May 10, 2019 11:09 AM EDT
News Briefing

Lam­bast­ed by AIDS ac­tivists about Tru­va­da pric­ing, Gilead of­fers CDC drug sup­ply deal; Fi­bro­Gen MACE mis­com­mu­ni­ca­tion leaves in­vestors dis­ori­ent­ed

Natalie Grover

Reporter

→ Chas­tised by AIDS ac­tivists for its pric­ing pol­i­cy on Tru­va­da, Gilead $GILD has agreed to pro­vide to CDC with up to 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times